Emerging Anti Carcinogenic Applications of Nimesulide: Therapeutic Benefits Beyond Its Primary Role in Pain Management

References

1. Saghaei E, Moini Zanjani T, Sabetkasaei M, Naseri K. Enhancement of antinociception by co-administrations of nefopam, morphine, and nimesulide in a rat model of neuropathic pain. Korean J Pain 2012; 25: 7-15. https://doi.org/10.3344/kjp.2012.25.1.7
2. Zhang YJ, Bao YJ, Dai Q, Yang WY, Cheng P, Zhu LM, et al. mTOR signaling is involved in indomethacin and nimesulide suppression of colorectal cancer cell growth via a COX-2 independent pathway. Ann Surg Oncol 2011; 18: 580-8. https://doi.org/10.1245/s10434-010-1268-9
3. Zhong B, Cai X, Yi X, Zhou A, Chen S, Su B. In vitro and in vivo effects of a cyclooxygenase-2 inhibitor nimesulide analog JCC76 in aromatase inhibitors-insensitive breast cancer cells. J Steroid Biochem Mol Biol 2011; 126: 10-8. https://doi.org/10.1016/j.jsbmb.2011.03.018
4. Kim BM, Won J, Maeng KA, Han YS, Yun YS, Hong SH. Nimesulide, a selective COX-2 inhibitor, acts synergistically with ionizing radiation against A549 human lung cancer cells through the activation of caspase-8 and caspase-3. Int J Oncol 2009; 34: 1467-73.
5. Ambike V, Adsule S, Ahmed F, Wang Z, Afrasiabi Z, Sinn E, et al. Copper conjugates of nimesulide Schiff bases targeting VEGF, COX and Bcl-2 in pancreatic cancer cells. J Inorg Biochem 2007; 101: 1517-24. https://doi.org/10.1016/j.jinorgbio.2007.06.028
6. Liu YJ, Ma YF, Zhang J, Zhao YP, Bai HL, Li SL. Synergistic lethal effect of mDRA-6 and nimesulide on human hepatocellular cancer cell line SMMC-7721. Ai Zheng 2008; 27: 374-8.
7. Paul AG, Sharma-Walia N, Chandran B. Targeting KSHV/ HHV-8 latency with COX-2 selective inhibitor nimesulide: a potential chemotherapeutic modality for primary effusion lymphoma. PLoS One 2011; 6: e24379. https://doi.org/10.1371/journal.pone.0024379
8. Nimesulide: patients still exposed to a risk of severe hepatitis. Prescrire Int 2011; 20: 125-6.